Company: HQL
Filing Date: 2025-12-08
Form Type: N-CSR
Source: 0001104659-25-119341
Chunk: 66

Company: abrdn Life Sciences Investors
Filing Date: 2025-12-08
Form: N-CSR
Chunk 66
---
's outstanding voting securities (which for this purpose and under the Investment Company Act, means the lesser of (1) 67% of the voting shares present in person or by proxy at a meeting at which more than 50% of the outstanding voting shares are present in person or by proxy, or (2) more than 50% of the outstanding voting shares).

| 1. | The Fund may not purchase or sell physical commodities or physical commodities contracts. |

| 2. | The Fund may not purchase or sell real estate; provided that the Fund may invest in securities secured by real estate or interests therein or issued by companies which invest in real estate or interests 
 therein.                                                                                                                                                                                                   |

| 3. | The Fund may not underwrite securities of other issuers, except to the extent that, in connection with the disposition of its portfolio securities, the Fund may be deemed an underwriter under federal or 
 state securities laws.                                                                                                                                                                                     |

| 4. | The Fund may issue senior securities to the extent permitted under the Investment Company Act and the rules and regulations thereunder. |

| 5. | The Fund may not make loans of money, which for the purposes of this restriction does not include the purchase of debt obligations in which the Fund may invest consistent with its |

| abrdn Life Sciences Investors | 49 |

Additional Information Regarding the Fund (Unaudited) (concluded)

| investment objective and policies. The Fund reserves the authority to enter into repurchase agreements and to make loans of its portfolio securities to qualified institutional investors, brokers,              
 dealers, banks or other financial institutions, so long as the terms of the loans are not inconsistent with the requirements of the Investment Company Act. Such loans of portfolio securities may not exceed an 
 aggregate amount of 33 1/3% of the Fund’s net assets.                                                                                                                                                            |

| 6. | The Fund may not invest less than 25% of its net assets in securities of Life Sciences Companies in the healthcare industry, except that, during periods in which the Investment Adviser |

| believes the healthcare industry is affected by adverse economic conditions, the Fund may temporarily have less than 25% of the value of its net assets so invested. |

Except as otherwise noted, all percentage limitations set forth above apply immediately after a purchase and a subsequent change in the applicable percentage resulting from market fluctuations does not require elimination of any security from the portfolio.

| 50 | abrdn Life Sciences Investors |

Dividend Reinvestment and Optional Cash Purchase Plan (